Tech & Science
Oncology
Pancreatic cancer drug daraxonrasib doubles survival in phase 3 trial
Daraxonrasib, a pan-RAS inhibitor developed by Revolution Medicines, doubled overall survival in advanced pancreatic ductal adenocarcinoma when added to first-line chemotherapy, according to phase 3 RASolute 302 results presented on 8 May 2026. Median survival rose from 8.7 to 17.4 months.